Oxidative Medicine and Cellular Longevity

Oxidative Medicine and Cellular Longevity / 2019 / Article

Review Article | Open Access

Volume 2019 |Article ID 8506195 | 14 pages | https://doi.org/10.1155/2019/8506195

The Beneficial Roles of SIRT1 in Drug-Induced Liver Injury

Academic Editor: Grzegorz Bartosz
Received12 Dec 2018
Revised27 Mar 2019
Accepted24 Apr 2019
Published01 Jul 2019

Abstract

Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) as a result of accumulated drugs in the human body metabolized into toxic agents and helps generate heavy oxidative stress, inflammation, and apoptosis, which induces necrosis in hepatocytes and ultimately damages the liver. Sirtuin 1 (SIRT1) is said to have multiple vital roles in cell proliferation, aging, and antistress systems of the human body. The levels of SIRT1 and its activation precisely modulate its critical role in the interaction between multiple step procedures of DILI. The nuclear factor kappa-light-chain-enhancer of activated B cell- (NF-κB-) mediated inflammation signaling pathway, reactive oxygen species (ROS), DNA damage, mitochondrial membrane potential collapse, and endoplasmic reticulum (ER) stress also contribute to aggravate DILI. Apoptosis is regarded as the terminal reaction followed by multiple signaling cascades including caspases, p53, and mitochondrial dysfunction which have been said to contribute in DILI. The SIRT1 activator is regarded as a potential candidate for DILI, because the former could inhibit signaling of p53, NF-κB, and ER stress. On the other hand, overexpression of SIRT1 also enhances the activation of antioxidant responses via Kelch-like ECH-associated protein 1- (Keap1-) nuclear factor- (erythroid-derived 2-) like 2 (Nrf2) signaling. The current manuscript will highlight the mechanism of DILI and the interaction of SIRT1 with various cytoplasmic factors leading to DILI along with the summary of potent SIRT1 agonists.

1. Introduction

Recently, drug-induced liver injury (DILI) has gained attention in hepatology and gastroenterology [1]. About 1% or less than of DILI cases are reported to cause liver injury, but it remained a frequent cause of acute liver failure throughout the developed countries [2]. The frequent etiology of DILI is linked with herbal products, antibiotics, chemotherapeutics, and immunomodulatory agents [3]. In recent decades, research has mainly focused on finding potential agents such as antitubercular [4], acetaminophen (APAP) [5], and inorganic heavy metals [6] that cause DILI. DILI gained much attention due to its importance in drug development along with its roles in failure or withdrawal of drug development [7]. The key issue related to treating DILI is to stop using the drug instantly that is a cause of liver injury in a dose-dependent fashion [8, 9]. The epidemiological studies of DILI showed that the dosage is a major determining factor of the risk that humans suffer from idiosyncratic adverse drug reaction [10]. However, dose is not the only factor that discriminates high- from low-risk drugs, which lowers the prediction of DILI and increases the number of patients suffering DILI [11]. In addition, immune response has also played an important role in DILI [12]. Infiltration of inflammatory cells into the liver is often perceived, hinting a role for the innate immune system [13, 14]. However, there is still no effective treatment available for DILI, hence attracting huge focus for in-depth studies on the mechanisms involved in it.

The sirtuins such as SIRT1 regulate a huge number of physiological phenomena particularly energy metabolism and stress responses [15, 16]. Besides deacetylation of histones, SIRT1 is also involved in controlling DNA repair, tissue regeneration, cell survival, inflammation, neuronal signaling, and circadian rhythms [17, 18]. Dynamic changes in SIRT1 expression and activity were observed in different DILI models [1922], which revealed its beneficial effects on APAP-induced liver injury [2224]. Moreover, mouse livers with inactive SIRT1 have more protection against endotoxemic liver injury by acetylating and activating NF-κB [25]. However, the overexpression of SIRT1 is linked with hepatocellular carcinoma cells (HCC) and tumor tissues, where it helped migration and invasion of HCC along with tumor metastasis in vivo by inducing epithelial-mesenchymal transition [26, 27]. Moreover, higher SIRT1 expression levels are linked with the total number and size of tumors [26]. Recently, a huge number of studies claimed that modulation in the expression of SIRT1 is linked with various aging-linked conditions [28].

Herein, we focused the potent effect of SIRT1 on ameliorating drug-induced liver injury (DILI), which may be a novel target for DILI treatment and other liver diseases, meanwhile shedding light on potent SIRT1 activators for further exploration of their roles in SIRT1 expression.

2. Drug-Induced Liver Injury (DILI)

Drug-induced liver injury (DILI) is interlinked with various factors such as oxidative stress, inflammation, and apoptosis (Figure 1). DILI is classified into two subtypes according to their different traits of hepatotoxicity, i.e., intrinsic or dose-dependent DILI and idiosyncratic DILI. The former type is predictable in humans or animal models, whereas the latter type of DILI is an unpredictable injury that cannot be explained by the known pharmacological properties.

2.1. DILI-Caused Oxidative Stress

APAP is currently the most studied drug, which causes intrinsic DILI [29, 30], while the mechanism of APAP-induced liver injury is much clear in oxidative stress, mitochondrial dysfunction, and immune response [3133]. APAP has higher absorption rate if administered orally, and the liver is the first site to metabolize and get damaged by various metabolites of APAP. APAP metabolism is accomplished dominantly via sulfation and glucuronidation. Another way of APAP metabolism is through cytochrome P450 (predominantly the 2E1 isoform), which metabolizes APAP into reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) by redox reactions. NAPQI leads to the depletion of glutathione (GSH) through attacking free thiols in mitochondria and cytoplasm [34]. Highly expressed NAPQI binds with proteins at sulfhydryl groups to form protein adducts [35], leading to oxidative stress and mitochondrial dysfunction, which is critical in hepatotoxicity [36]. During dysfunction of mitochondria, accumulation of great amounts of reactive oxygen species (ROS) has been reported that causes oxidative stress and activates signaling cascades (Figure 1). However, some drugs that cause DILI have a variety of ways to accumulate ROS [37].

ROS are also able to activate cytoprotective signaling in the cells such as the nuclear factor E2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1)/heme oxygenase 1 (HO-1) pathway [38]. Under normal conditions, newly translated Nrf2 gets attached with Keap1 and is being degraded by p62-dependent autophagy to maintain lower levels of Nrf2 in the cytoplasm under normal condition [39]. However, when the Keap1 is oxidized or bound with NAPQI, the Nrf2 gets disassociated from Keap1 and translocated into the nucleus where it binds with the antioxidant response element (ARE) to activate antioxidant genes [40].

2.2. DILI-Caused Organelle Damage

The damage of organelles is another critical factor that leads to necrosis or apoptosis of hepatocytes in DILI [41, 42]. Mitochondria play an important role in supplying energy to various parts of cells, but any slight dysfunction may cause necrosis [41, 43]. The induction of mitochondrial permeability transition (MPT) enhances permeability in the mitochondrial membranes and allows the exit of molecules of variable sizes [44]. Furthermore, the collapse of mitochondrial membrane potential and the release of cell death-related proteins lead to apoptosis [45]. ROS is also contributed by the MPT pore, which in turn exaggerates oxidative stress and DNA damage, while on the contrary, β-oxidation and adenosine triphosphate (ATP) production are also regulated accordingly [46]. The ER stress also plays a critical role in APAP-mediated hepatotoxicity and helps synthesize proteins and their folding and secretion [47]. Once the function of ER is disturbed by overdosed APAP, its metabolites cause a severe dysfunction that leads to accumulating misfolded proteins and creating ER stress [48, 49]. The underlying mechanism of APAP-induced ER stress is not much clear yet, but various hypotheses explained the process quiet reasonably. One of the opinions is that APAP oxidizes ER oxidoreductases endoplasmic reticulum protein 72 (Erp72) and protein disulfide isomerase (PDI) of hepatocellular microsomes [50, 51]. NAPQI gets covalently attached with microsomal protein calreticulin and PDI, which have crucial roles in protein folding and create ER stress [52]. Moreover, accumulation of various ROS and disregulation in proper mitochondrial functions contribute to ER stress [53].

2.3. DILI-Caused Immune Responses

Various types of immune responses are also obligatory in DILI. The interaction between DILI and the immune system in both innate immune responses and adaptive immune response has a clear and detailed mechanism reported by multiple hypotheses. In innate immune response, the main hypothesis pointed out that neoantigen stimulates cells and causes inflammation by binding to scavenger receptors (SCRs), mannitol receptors (MRs), and Toll-like receptors (TLRs) in macrophages [54]. The activation of killer cells (KC) is beneficial in ameliorating APAP-induced hepatotoxicity through anti-inflammatory effects [55]. High-mobility group box 1 (HMGB1) protein is believed to activate immune cells as damage-associated molecular patterns (DAMPs) [56]. HMGB1 activates KC by releasing cytokines (TNF-α, interferon γ (IFNγ), and IL-1) [57, 58], while the roles of NK/NKT cells remained controversial yet, because of the secretion of cytokines (IFNγ and IL-4) that ameliorate liver injury [59, 60]. However, other studies argued that the significant differences exist in cytokine levels produced by NKT cell-deficient mice [61, 62]. In adaptive immune response, APAP along with its metabolites acts as haptens that bind to liver proteins. These drug-protein adducts are then processed by antigen-presenting cells (APC), and the antigen associates with major histocompatibility complex (MHC) class II molecules. After that, CD4 T-cell gets activated resulting in adaptive immune response, which then triggers CD8 cytotoxic T-cell activation leading to the expression of FasL, TNF-α, and other proteins that mediates cell apoptosis [63].

2.4. Existing Treatments of DILI

Following the recommended guidelines, three main treatments are prescribed when DILI gets diagnosed. First of them, withdrawal of the drugs or immediately discontinuation of drugs that are not indispensable for control of underlying diseases can resume liver health up to 95% or even lead to absolute recovery of the liver [64]. It is believed that drugs need to be withdrawn when the elevation of ALT or AST is <3 times of the upper limit of normal (ULN) and without clinical symptoms, even if those are not necessarily defined as liver-injuring drugs [65]. And the dosage of hepatotoxic drugs should be reduced when it is necessary in controlling other diseases and there are no other substitutable agents [65]. During pregnancy in DILI, not only the withdrawal of drugs is crucial but also the careful monitoring of the fetus is recommended or even in certain cases, the abortion can also be considered depending on the severity of DILI [65].

In the second step, the pharmacotherapy is recommended where N-Acetylcysteine (NAC) is able to clear out free radicals. NAC is recommended by ACG Clinical Guidelines published for the diagnosis and treatment of DILI and the early stage of acute liver failure (ALF) [66]. However, NAC is not recommended for children with acute liver failure [66]. Besides, magnesium isoglycyrrhizinate is recently approved to treat acute DILI by the Chinese Food and Drug Administration (CFDA), due to its efficacy of reducing the serum ALT level in randomized controlled studies [67]. Finally, at the 3rd step, liver transplantation is recommended in case of severe coagulation disorders, encephalopathy, and decompensated cirrhosis [68].

3. SIRT1 Helps Alleviate Oxidative Stress in DILI

DILI increases lipogenesis and ultimately the generation of ROS within cells while inhibiting mitochondrial fatty acid oxidation (FAO) (Figure 2). SIRT1 mediates responses to check lipogenesis and directly inhibits generation of ROS or alternatively via upregulation of mitochondrial FAO (Figure 2). When the individual is exposed to various harmful irritants/pollutants, a large amount of ROS and reactive nitrogen species (RNS) is produced. ROS enhances the expression of proteins and genes in the cellular antioxidant system, such as manganese superoxide dismutase (MnSOD), catalase (CAT), glutathione peroxidase 1 (GPX1), and GSH, which largely eliminates ROS. Under heavy oxidative stress, the excessively generated ROS or RNS disrupts the cellular homeostasis of oxidants and antioxidants, or in severe and highly reactive species, the tissues get damaged. SIRT1 activates various signaling cascades to alleviate oxidative stress, which is mainly reflected by the increase of lipid peroxidation and improvement of mitochondrial functions.

3.1. Lipid Oxidation

The ROS mediated by decreased mitochondrial FAO and increased lipogenesis play an important role in liver and other tissues [69]. Under normal conditions, both cellular oxidants and antioxidants are in the state of coordination and dynamic balance, maintaining a wide range of physiological and biochemical reactions along with various stress responses.

Excessive abuse of ethanol is a dominant factor that induces lipid deposition in the liver via depleting GSH levels and leading to ROS-mediated liver damages, which is linked with hepatic steatosis, hepatic fibrosis, and even hepatocellular carcinoma [7072]. All this leads to two situations, i.e., either an increased level of fatty acid synthesis or a decreased level of fatty acid metabolism in the liver. AMP-activated protein kinase (AMPK) plays a key role in regulating fatty acid synthesis and metabolism [73]. Acetyl-CoA carboxylase (ACC) is a rate-limiting enzyme during fatty acid biosynthesis. Studies showed that ethanol/alcohol can inactivate AMPK, which further inhibits the phosphorylation of ACC to promote the fatty acid biosynthesis [74]. Methyl ferulic acid (MFA), a biologically active monomer extracted and purified from the Chinese herbal plant Securidaca inappendiculata Hasskarl, improves acute liver damage induced by ethanol closely associated with upregulation of the SIRT1 levels [75].

The peroxisome proliferator-activated receptors (PPAR-α, PPAR-β, and PPAR-γ) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes involved in multiple cellular metabolisms, especially in energy metabolism. PPAR-α is expressed in the liver cells and helps promote oxidation of lipids. Carnitine palmitoyl-transferase 1A (CPT1A) is a rate-limiting enzyme taking part in β-oxidation of fatty acids [76]. Ethanol can inhibit the activation of PPAR-α and CPT1, which weakens the lipid oxidation and leads to the lipid deposition in the livers [77]. SIRT1 activation can increase the level of PPAR-α and peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) [78], which is the coactivator of PPAR-α to exhibit the protective effects during liver injury [79]. MFA has a positive effect on ethanol-induced hepatic steatosis by increasing the levels of AMPK, FoxO1, SIRT1, PPAR-α, and CPT-1A. PPAR-γ is well stated to take part in the promotion of the biosynthesis of lipids within the liver [80]. Moreover, PPAR-γ is repressed by SIRT1 to promote lipogenesis [81]. Activation of SIRT1, on the one hand, increases FAO expression by stimulating the PPAR-α/PGC-1α axis and decreases lipogenesis by targeting PPAR-γ, leading to amelioration of lipid metabolism and ultimately improvement of DILI. Consistent with this, isoniazid-rifampicin-induced liver injury was successfully ameliorated by upregulation of the expression of SIRT1 [79].

In addition, SIRT1 and AMPK combined and work in the fatty acid metabolism. It is further said that thymoquinone (TQ) activates AMPK to reduce the alcohol-mediated liver injury by upregulating SIRT1 [82]. Alcohol consumption alters lipid homeostasis particularly by decreasing PPAR expression and increased activation of sterol regulatory element-binding proteins (SREBP-1) via an AMPK-dependent way [83]. Some evidences showed that SIRT1 was able to stimulate AMPK activation via regulating liver kinase B-1 (LKB1) which is a major serine/threonine kinase which binds closely with AMPK to direct the activation of the downstream kinases [84]. It has also been stated that SIRT1 can inhibit the expression of SREBP-1 and fatty acid synthase (FASN), which is the well-known mechanism of resveratrol’s protective effect on high-fructose corn syrup-induced hepatic dysfunction [85].

SIRT1/PGC-1α cascade may act as upstream of the Nrf2 signaling pathway to alleviate DILI. Upon activation, Nrf2 translocated into the nucleus where it binds with the antioxidant response element (ARE) and activates antioxidant genes. Nfr2 intentionally activates HMOX1 that translated into HO-1 and helps express NAD(P)H quinone dehydrogenase 1 (NQO1) and the glutamate-cysteine ligase catalytic/modifier subunit (GCLC/GCLM). NQO1 is the regulator of lipid metabolism, while HO-1 actively metabolizes heme to scavenge free radicals in the cytoplasm. GCLC and GCLM regulate the cellular redox status to remove ROS quite efficiently [86]. Furthermore, Nrf2 plays a critical role in transcriptional upregulation of ATP-binding cassette (ABC) transporters essential for cellular defense in response to oxidative stress [87]. SIRT1 transforms the free fatty acids into glucose by acetylation and activation of PGC-1α and FoxO1 in short-term fasting, along with the increase in Nrf2 transcription and activation [88]. Fasting can induce the accumulation of cAMP, but cAMP/PKA and SIRT1 are the upstream regulatory factors that rapidly activate Nrf2-ABC transporters, which help to clear various chemicals and biliary excretions in the liver cells in response to chemical stimulants and liver injury [86, 88].

3.2. Mitochondrial Function

During oxidative stress, reduction in mitochondrial membrane potential (MMP) due to excessive ROS and mitochondrial permeability transition pores (MPTP) are two major factors causing mitochondrial damage. The interactions between excessive ROS and the hepatic mitochondrial membranes are major indicators under oxidative stress. Certain studies have found that D-galactosamine/lipopolysaccharide- (D-GalN/LPS-) induced acute liver injury in mouse models has a higher production level of malondialdehyde (MDA) [89]. An end product of lipid hydroperoxide (LPO) may lead to decreased mitochondrial membrane fluidity, even under severe damages [90]. For this kind of mitochondrial membrane damage or lipid peroxidation caused by excessive ROS, one of the effective ways is to enhance the activation of the cellular antioxidant system to eliminate heavy burst of ROS. It is further said that mitochondrial antioxidant defense was enhanced by curcumin when challenged with D-GalN/LPS [21]. Curcumin is a chain-breaking antioxidant which is a lipophilic substance that can be incorporated into the biofilms that directly protect cells from ROS. Curcumin modulated the mRNA expression of SIRT1 in liver cells that regulates the activity of FoxO3 and alters the expression of MnSOD and Cat [16, 21].

Mitochondrial permeability transition pores (MPTP) play a vital role in maintaining mitochondrial physiology and performance. A sharp rise in ROS generation leads to the opening of MPTP, resulting in the imbalance of H+ on the inner membrane of mitochondria, destroys membrane proteins, inhibits ATP synthesis, and causes mitochondrial swelling, all of which may exacerbate necrotic or apoptotic cascades leading to rapid cell death [91]. Resveratrol is able to reinstate SIRT1 activation which resists against oxidative stress through the upregulation of antioxidants such as superoxide dismutase 2 (SOD2), which inhibits the mitochondrial injury by swapping out excessively generated ROS [92]. It has also been found that cyclosporine A (CsA) can inhibit MPTP constitution protein cyclophilin D to protect mitochondrial functional integrity under severe shocks [93].

An enhancement in mitochondrial biogenesis is also an important way to improve mitochondrial functionality. For instance, cadmium (Cd) causes mitochondrial swelling and checks mitochondrial activity including oxidant capacity and ATP synthesis [94]. By acting on melatonin receptor 1 (MTR1), melatonin activates the SIRT1/PGC-1 signaling pathway, allowing SIRT1 to interact with PGC-1 in deacetylation, thus improving the activation of PGC-1. Moreover, it can accelerate mitochondrial biogenesis and maintain mitochondrial physiology [95]. In addition to it, AMPK is situated at the upstream of the SIRT1 pathway and Cd treatment leads to a significant increase in the pAMPK protein level but melatonin does not change AMPK signaling [96].

4. SIRT1 Decreases the Inflammatory Responses in DILI

There are numerous types of immunocytes that initiate inflammatory reactions in the liver including macrophage Kupffer cells (KCs), T-cells, B-cells, and natural killer (NK) cells. All these inflammatory responders play an important role in the drug-induced liver injury. Heavy ROS activates a variety of inflammatory factors, but SIRT1 along with Nrf2 efficiently inhibits these activated inflammatory responses in the liver cells (Figure 3). The mechanism of inflammation is elucidated mainly in the NF-κB signaling pathway and various SIRT1 activity-related agents like HMGB1 and SRT1720.

4.1. NF-κB Signaling

NF-κB is a dimer protein that is generally composed of two functional subunits (p65 and p50) and binds to its natural inhibitory protein IκB, which can prevent NF-κB from nuclear translocation and regulation of related target genes. Once the hepatocyte gets stimulated, the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88) receptor receives the stimulant that further activates the three subunits of the MPAK (p38, JNK, and ERK) signaling pathway. The regulation of proinflammatory cytokines has significant contribution in activation of the NF-κB pathway. Various compounds particularly ethanol [97], carbon tetrachloride (CCl4) [98], APAP [22], and mercuric chloride [86] help to release numerous proinflammatory cytokines and subsequently cause inflammations.

In ethanol-induced hepatic injury, lipid peroxidation adducts such as 4-HNE and MDA are formed which aid elimination of GSH and accumulation of TG and enhanced the release of TNF-α, TGF-β, and IL-6 [99]. These various cytokines can activate the MPAK and NF-κB signaling cascades. Moreover, the plant extracts of Ulmus davidiana var. japonica (RUE) treatment can inhibit the activation of MAPKs and NF-κB signaling, reducing the expression of IL-6, IL-1β, and IL-18 and the downstream targets of NF-κB signaling cascades. Moreover, RUE increases the expression of SIRT1 and ultimately stimulated the activation of AMPK-α and increased the expression of PGC-1α, thus reducing the fatty acid oxidation [97].

The higher ROS production can result in hepatocyte damage, and persistent accumulation of ROS leads to inflammation and release of TNF-α [100]. In HgCl2-induced liver injury, Hg2+ gets tightly complexed with hydrosulphonyl moieties and depletes intracellular hydrosulphonyl moieties and leading to the generation of more ROS [86]. TNF-α binds to tumor necrosis factor receptors (TNFR) to form a complex that binds with TNFR type 1-associated death domain protein (TRADD) and to activate p38 MAPK and NF-κB [101]. It was also suggested that luteolin reduces activation of NF-κB and phosphorylation of p38 under HgCl2-induced injury. Additionally, luteolin also activates SIRT1 which is inhibited by HgCl2. SIRT1 directly reduces NF-κB and p53 activation via promoting deacetylation of NF-κB at p65 and p53subunits [102, 103]. Furthermore, SIRT1 activates the Nrf2/Keap1 pathway to decrease ROS generation and their accumulation in the cytoplasm [88]. Hence, luteolin-mediated SIRT1 plays an important function in regulating inflammation, apoptosis, and antioxidant defense systems in HgCl2-induced hepatotoxicity.

Immune response is also modulated by protective effects of SIRT1 during DILI. It is revealed that concanavalin A (ConA) promotes the release of proinflammatory cytokines (TNF-α, IFNγ) which lead to liver injury [104]. Recently, SIRT1 expression at transcriptional and translational levels was increased in activated T-cells and knockout of SIRT1 resulted in an abnormal increase of T-cell activation and lowered the tolerance of CD4+ T-cells [105]. An abnormal increase in T-cell activation and defects in innate immune responses to microbes were clear in patients with acute liver failures [63]. With T-cells being activated overly by ConA, the inflammatory responses can lead to hepatitis or in certain cases resulted in autoimmune diseases. Treatment with salvianolic acid A (SalA) enhanced the expression of SIRT1, which might be used to restrict the abnormal T-cell activation restoring antimicrobial responses in patients with ALF. On the contrary, SalA is also able to negatively regulate NF-κB-dependent inflammatory cascades by inhibiting IKKβ. It is clear that the protective impact of SalA has an important part in ConA-induced inflammations.

In the NF-κB signaling, instead of the upregulation of expression of proinflammatory cytokines, the regulation of TLR/MyD88 is also an important factor that negatively affects inflammations [101]. Downregulation of TLR4 reduces NF-κB activation, while dimethylnitrosamine (DMN) causes oxidative stress to produce superfluous ROS, which is the igniting agent of inflammation [106]. Moreover, DMN is able to aid in releasing proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and further aggravate the activation of NF-κB signaling. Meanwhile, NF-κB activation modulates iNOS that leads to the production of NO and causes inflammation and necrosis. Dioscin inhibits expression of TLR4, MyD88, p50, p65, TNF-α, IL-1β, IL-6, iNOS, and NO at transcriptional levels and effectively improves the DMN-induced acute liver injury [106].

Trace elements potentially target the modulation of NF-κB. In CCl4-induced liver injury, excessive ROS may likely activate Kupffer cells and help releasing proinflammatory cytokines. Grape seed oil (GSO) can upregulate the gene expression of SIRT1 to give protection by downregulating NF-κB. Interestingly, these trace elements can be the cofactors for many enzymes to perform their roles in SODs (CuZnSOD and MnSOD) and are involved in oxidative stress and possible inflammations [107].

4.2. Other Factors

High-mobility group protein box 1 (HMGB1) is reported to play an important role in sepsis, and it can activate innate immune cells to give rise to antigen-presenting cells [56]. Under normal condition, HMGB1 resides in the nucleus that remained bound with DNA to stabilize nucleosomes and facilitates mRNA expression at transcriptional levels [82]. Extracellular HMGB1 release can cause inflammation and stimulate innate immune cell migration and activation via nucleocytoplasmic HMGB1 translocation. Acetylation is important for activated HMGB1 to release from the nucleus to the cytoplasm. SIRT1 may regulate HMGB1 translocation via deacetylation [108]. Resveratrol can upregulate SIRT1 to inhibit inflammation and hence attenuated severe liver injury following sepsis [109]. Moreover, SRT1720 reduces the release of inflammatory cytokines (TNF-α, IL-6) to block the inflammatory reactions [110].

5. SIRT 1 Alleviates Apoptosis in DILI

Apoptosis ends up with the DNA fragmentation which can intensify oxidative stress along with inflammation and leads to irreversible cell death adopting the apoptotic pathway or necrosis [107]. In the process of apoptosis, upstream factors of apoptosis have interaction with related receptors (TNFR1/2, Fas, and DR3/4/5) and further activate the apoptotic signaling pathways, which can be concluded into TNF/TNFR, Fas/FasL, and mitochondrion-mediated and endoplasmic reticulum-mediated pathways. Then the apoptotic genes get activated and DNase or caspases will execute apoptosis to induce DNA fragmentation.

5.1. The Mitochondrion-Mediated Signaling Pathway

The mitochondrial membrane integrity is essential for ethanol-induced cell death [111]. When the apoptosis fragments stimulate the hepatocyte, cytochrome C (CytC) and the apoptosis-inducing factor (AIF) restricted to the mitochondria are released into the cytosol. CytC triggers caspase-3 and executes the caspase series, which can directly result in apoptosis. AIF, which is a proapoptotic protein, is independent on the caspase pathway and directly induces apoptotic cell death. According to the study, ethanol treatment enhances the release of CytC and AIF, thus promoting apoptosis and subsequent liver injury. However, carnosic acid (CA) can improve the ethanol-induced liver injury via the SIRT1/p66Shc pathway [112]. CA enhances SIRT1 expression which is being inhibited by ethanol treatment. It is known that SIRT1 is a crucial factor in the amelioration of ethanol-induced mitochondrial damage under heavy oxidative stress. Growing studies have indicated that SIRT1 can restrain the expression of p66Shc at transcriptional levels by decreasing acetylation of p66Shc promoter-bound histone H3 [112]. Moreover, p66Shc suppresses its interaction with mitochondrial CytC to reduce apoptosis [113]. Similarly, SIRT1 has a similar effect on AIF. CA can significantly attenuate ethanol-induced liver injury through a SIRT1/p66Shc-mediated mitochondrial pathway. In addition, it has shown that SalA can decrease the expression of caspase-3 and p66Shc and increase the expression of Bcl-xL, which has been well documented that SalA has a protective effect on the concanavalin A- (ConA-) induced hepatocyte apoptosis. The result has shown that pretreatment of SalA augmented SIRT1 expression and inhibited p66Shc expression to reverse the upregulation of p66Shc expression by ConA [104]. Moreover, the Bcl-2 family can inhibit apoptosis while Bak promotes cell apoptosis in the mitochondrial signaling pathway [106].

5.2. DNA Damage and p53 Pathway

Not only the excessive ROS but toxic agents (including CCl4 [98], APAP [22], and cadmium [94]) and UV radiation [107] could lead to DNA damage and ultimately apoptosis. CCl4 increases the iNOS level releasing NO into the cells, which combines with superoxide ions to form peroxynitrite and metabolically active trichloromethyl radicals that results in either direct or indirect DNA damage to promote apoptosis [107]. Furthermore, the expression of NO by iNOS can also be regulated by the activation of NF-κB, mainly by oxidative stress, and CCl4 can indirectly upregulate the series of caspases, the dominant players in apoptosis. GSO protected CCl4-induced liver injury via inhibiting caspase-3 activation, through activation of SIRT1, which blocks the expression of NF-κB and decreases the production of NO [107].

On the other hand, p53 is the sensor of DNA damage and cell death and it promotes apoptosis by regulating the levels of caspase-9, caspase-3, and Bcl-2 family members [114]. Few studies claimed that dioscin has a positive effect on DMN-induced acute liver injury and inhibitory effect on hepatocyte apoptosis by activating SIRT1 [106, 115]. Interferon regulatory factor 9 (IRF9) plays a key role in inducing apoptosis by decreasing the SIRT1 expression level and increasing p53 expression [106, 116]. In addition to it, dioscin significantly decreased the levels of IRF9, p53, Bax, caspase-3, caspase-9, Fas, and FasL, while it increased the levels of SIRT1 and Bcl-2 [106]. Therefore, dioscin can be a quite efficient protector to improve the cell apoptosis and DMN-induced acute liver injury.

In addition, it has been illuminated that the MAPK-p53 axis is a major signaling pathway involved in the apoptosis of hepatocytes. Furthermore, the activation of p38 MAPK can regulate p53 transcriptional activation and translocation into the nucleus [117]. Similarly, the increased level of MAPK p38 can also induce excessive ROS production and further modulates p53-mediated apoptosis in human hepatocytes [97]. RUE was reported to negatively regulate MAPK activity and downregulate p53 expression blocking apoptosis in chronic alcohol-mediated liver injury. Moreover, pterostilbene (Pte), a natural dimethylated analog of resveratrol from blueberries, alleviates sepsis-induced liver injury by reducing the expression of acetylated (Ac) FoxO1, Ac-p53, and p38MAPK activities and the potential mechanism is associated with SIRT1 signaling activation [118, 119].

5.3. ER Stress

ER, which is closely associated with DILI, also contributes to apoptosis in intrinsic and extrinsic pathways. Through the intrinsic pathway, Ca2+ was released from ER lumen by ER-localized Bak, resulting from the conformational changes and oligomerization of Bak and Bax at the ER membrane [120]. Disruption of the Ca2+ pool activates calpain in the cytosol and converts procaspase-12 to caspase-12 thus activating caspase-9 and caspase-3 to approach apoptosis [121]. On the other hand, the released Ca2+ is taken up by mitochondria, leading to collapse of inner membrane potential and subsequently the initiation of apoptosis [122]. On the other hand, in the extrinsic pathway, IRE forms the complex with TNF receptor-associated factor 2 (TRAF2) and apoptosis signal-regulating kinase 1 (ASK1) to activate JNK [123]. Han et al. reported that reduced silent information regulator 1 signaling exacerbates sepsis-induced ER stress in sepsis-induced myocardial injury [124]. ER stress has recently emerged as major regulators in drug-induced liver injury [49]. Further experiments are needed to confirm whether SIRT1 is involved in ER stress in DILLI.

5.4. TNF/TRAF Pathway

TNF-α is the key factor that mediates the association between oxidative stress and NF-κB. NF-κB activates a series of genes such as c-IAP1 and c-IAP2 to inhibit TNF-α-induced apoptosis by suppressing the activity of caspases [125, 126]. IAPs inhibit CytC-induced proteolytic processing of caspase-3. However, the recruitment of c-IAP1 and c-IAP2 in response to TNF-α, which is dependent on the interaction with TRAF1 or TRAF2, is indispensable to inhibit apical caspase-8 [125]. Multiple studies showed that SIRT1 signaling activation attenuates DILI by reducing the TNF/TRAF pathway and finally inhibits hepatic apoptosis [118, 127, 128].

5.5. Other Mechanisms and Connections

Meanwhile, certain mechanisms get interacted with each other in DILI. SIRT1 is also the activator of autophagy in DILI and provides potential protection against hepatotoxicity. Many of the in vivo studies depicted autophagy as an important mechanism which involves lysosomal degradation to get rid of the damaged cellular inclusions in order to maintain homeostasis particularly in hepatocytes [129]. In continuation, autophagy clears excessive lipids/fat molecules to ameliorate hepatocyte steatosis [130]. In SIRT1-mediated autophagy, FoxO3 poses a crucial part in the forming of amplification of stress-linked autophagy. Overexpression of the negative form of FoxO3a abolishes the induction of ethanol-induced autophagy [131]. Resveratrol activates SIRT1, and the expression of autophagy-linked genes was improved mainly because of the deacetylation by SIRT1. Furthermore, FoxO3a mice were treated with ethanol exhibiting decreased expression of autophagy-related genes [131]. This manuscript suggested the importance of FoxO3a in SIRT1-linked autophagy. Besides, acetylate FoxO1 was hinted to promote autophagy by binding to Atg7 in cancer cells [23]. The FoxO family has diverse biological functions including cell cycle, apoptosis, oxidative stress, DNA damage repair, and glucose metabolism; thus, attention is needed to be paid in the SIRT1-autophagy activation process [131].

Self-protection mechanism such as regeneration is also involved in the SIRT1-activated DILI attenuation. The SIRT1 agonist, resveratrol, was applied as pretreatment before APAP administration. SIRT1 activation represses p53 signaling, thus inducing cell proliferation-associated proteins such as CDK4, PCNA, and cyclin D1 to promote proliferation of hepatocytes [79].

It is now clear to say that SIRT1 plays a key role in ameliorating DILI by inhibiting oxidative stress, inflammation, and apoptosis by interacting with other signaling pathways, including p53, HMGB1, and autophagy (Figure 4). In DILI, oxidative stress-causing agents also contribute to apoptosis. The efflux of cellular ROS can attack DNA to create DNA lesions and finally lead to apoptosis or necrosis in the cells [37]. These DNA fragments can aggravate the oxidative stress in return. Inflammation can also be developed into apoptosis, and both mechanisms are regulated by the p38 MAPK pathway. The p38 can significantly stimulate p53 function, which plays a critical role in the apoptosis induction, while p38-MAPK can promote phosphorylation of IκB (inhibitor of NF-κB) which dissociates with NF-κB to induce inflammation. There are some reliable evidences that showed that NF-κB can be suppressed by luteolin and decrease the relative protein levels of Bax and increase the Bcl-2 levels, which can inhibit cell apoptosis [86].

There is also a close relation between oxidative stress and inflammation. Nrf2 has a negative effect on TNF-α expression, playing a crucial role during oxidative stress and inducing the production of the downstream target proteins of Nrf2 such as NQO1, HO-1, and SOD [132]. Therefore, we conclude that Nrf2 is a key regulator in antioxidant and anti-inflammatory defense systems.

6. Outlook

Over the last several decades, investigators continued to broaden our knowledge in understanding the intracellular signaling mechanisms leading to DILI in hepatocytes in experimental animals and humans. However, DILI is still a critical problem that plagues individuals across the world, largely due to the increased consumption of drugs and the lack of specific therapies and antidotes. Recent studies highlighted the therapeutic roles of SIRT1 in treating DILI. Therefore, clinical application of SIRT1 activators (Table 1) is the putative therapeutic approach against DILI. However, despite the promising findings from in vitro and in vivo studies, supporting evidence from clinical studies is lacking. Furthermore, the application of powerful genomic, proteomic, transcriptomic, and metabonomic technologies holds promise to connect SIRT1 to the established mechanisms that will enhance our understanding of the SIRT1 role in DILI. In-depth insight into the therapeutic role of SIRT1 with a goal toward modification and prevention may be fruitful in light of medical treatment of DILI limited by the deficiency of specific therapies and antidotes currently available.


CompoundsToxicMechanismsRef.
NameDosageNameDosage

Dioscin80, 40, and 20 mg/kg (mice)
60, 30, and 15 mg/kg (rats)
DMN14 mg/mg (mice)
10 mg/mg (rats)
SIRT1↑, Nrf2↑, and Bcl-2↑
p53↓, Fas↓, and FasL↓
[99]
GSO3.7 g/kg (rats)CCl41 ml/kg (rats)SIRT1↑
NF-κB↓, CYP2E1↓
[100]
Luteolin100 mg/kg (mice)HgCl24 mg/kg (mice)SIRT1↑, Nrf2↑
p38↓, TNF-α
[72]
SalB15, 30 mg/kg (rats)Ethanol6 g/kg (rats)SIRT1↑
p53↓, NF-κB↓
[96]
RUE100 mg/kg (mice)Ethanol1 g/kg (mice)SIRT1↑, AMPK↑
p65↓, SREBP-1↓
[89]
MFA5, 10, and 10 mg/kg (rats)Ethanol5% (, rats)SIRT1↑, PPAR-α
MAPK↓, p-ACC↓
[67]
TQ20, 40 mg/kg (mice)Ethanol5 g/kg (mice)SIRT1↑, AMPK↑[74]
CA20, 40 mg/kg (rats)Ethanol6 g/kg (rats)SIRT1↑
p66Shc↓
[105]
Resveratrol500 mg/kg (Rats)HFCS20% (, rats)SIRT1↑, IRS-1↑
iNOS↓
[77]
Quercetin
SRT1720
Resveratrol
50 mg/kg (rats)
5 mg/kg (rats)
2.3 mg/kg (rats)
D-GalN
LPS
400 mg/kg (rats)
10 μg/kg (rats)
SIRT1↑, HO-1↑
Bilirubin↓
[35]
Melatonin0.5 μM (HepG2)Cadmium2.5, 5, and 10 μM (HepG2)SIRT1↑
Ac-PGC-1α
[88]
STR172010, 20 mg/kg (mice)EE10 mg/kg (mice)SIRT1↑, FXR/HNF1α
IL-6↓, TNF-α
[103]
SalA15, 25 mg/kg (mice)ConA18 mg/kg (mice)SIRT1↑
p66Shc↓
[97]
Resveratrol25, 50, and 100 mg/kg (mice)APAP400 mg/kg (mice)SIRT1↑, cyclin D1↑
p53↓, CYP2E1↓
[23]
Resveratrol
CAY10591
30 mg/kg (rats)
0.5 mg/kg (rats)
APAP1 g/kg (rats)SIRT1↑[24]
Resveratrol100 mg/kg (mice)INH
RIF
50 mg/kg (mice)
100 mg/kg (mice)
SIRT1↑
PPAR-γ
[71]

DMN: dimethylnitrosamine; CCl4: carbon tetrachloride; GSO: grape seed oil; MFA: methyl ferulic acid; EE: 17α-ethinylestradiol; RUE: root bark of Ulmus davidiana var. japonica; D-GalN: D-galactosamine; LPS: lipopolysaccharide; TQ: thymoquinone; CA: carnosic acid; HFCS: high-fructose corn syrup; CLP: cecal ligation and puncture; SalB: salvianolic acid B; SalA: salvianolic acid A; ConA: concanavalin; Ref.: reference.

Conflicts of Interest

The authors declare no conflict of interest for the submission of this review article.

Authors’ Contributions

Chunpeng Wan and Weifeng Huang conceptualized the study; Tingdong Yan and Jinlong Huang wrote the manuscript and performed the original draft preparation; Weifeng Huang and Muhammad Farrukh Nisar wrote, reviewed, and edited the manuscript; Chunpeng Wan supervised the study; Weifeng Huang performed project administration; Tingdong Yan performed funding acquisition.

Acknowledgments

This research was funded by the National Natural Science Foundation of China (Grant no. 31500286 to C. Wan and Grant no. 81100281 to W. Huang).

Supplementary Materials

SIRT1 plays a vital role in drug-induced liver injury. SIRT1 can regulate the levels of inflammation and oxidative stress, which are the main damages caused by DILI. During DILI, the repressed SIRT1 increases the immune response and oxidative damage and ultimately leads to the death of hepatocyte, in the form of apoptosis, namely, programmed cell death, or cell necrosis, both of which are the cause of liver injury. On the other hand, enhancing SIRT1 expression or activity of SIRT1 protects the liver against drug-induced injury. SIRT1 alleviates oxidative stress by targeting AMPK, Nrf2, PGC-1α, and FoxOs and improves mitochondrial function. The mechanism of inflammation is elucidated mainly in the NF-κB signaling pathway which is tightly regulated by SIRT1. (Supplementary Materials)

References

  1. N. Chalasani, H. L. Bonkovsky, R. Fontana et al., “Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study,” Gastroenterology, vol. 148, no. 7, pp. 1340–1352.e7, 2015. View at: Publisher Site | Google Scholar
  2. G. A. Kullak-Ublick, R. J. Andrade, M. Merz et al., “Drug-induced liver injury: recent advances in diagnosis and risk assessment,” Gut, vol. 66, no. 6, pp. 1154–1164, 2017. View at: Publisher Site | Google Scholar
  3. M. Ettel, G. A. Gonzalez, S. Gera et al., “Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center,” Human Pathology, vol. 68, pp. 92–98, 2017. View at: Publisher Site | Google Scholar
  4. T. E. Chang, Y. S. Huang, C. H. Chang, C. L. Perng, Y. H. Huang, and M. C. Hou, “The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis,” Journal of the Chinese Medical Association, vol. 81, no. 2, pp. 111–118, 2018. View at: Publisher Site | Google Scholar
  5. C. M. Florkowski, R. E. Ferner, and A. F. Jones, “Liver transplantation after paracetamol overdose,” BMJ, vol. 303, no. 6799, p. 420, 1991. View at: Publisher Site | Google Scholar
  6. M. P. Waalkes, M. R. Anver, and B. A. Diwan, “Chronic toxic and carcinogenic effects of oral cadmium in the Noble (NBL/Cr) rat: induction of neoplastic and proliferative lesions of the adrenal, kidney, prostate, and testes,” Journal of Toxicology and Environmental Health, Part A, vol. 58, no. 4, pp. 199–214, 1999. View at: Google Scholar
  7. G. Luo, Y. Shen, L. Yang, A. Lu, and Z. Xiang, “A review of drug-induced liver injury databases,” Archives of Toxicology, vol. 91, no. 9, pp. 3039–3049, 2017. View at: Publisher Site | Google Scholar
  8. J. Polson, W. M. Lee, and American Association for the Study of Liver Disease, “AASLD position paper: the management of acute liver failure,” Hepatology, vol. 41, no. 5, pp. 1179–1197, 2005. View at: Publisher Site | Google Scholar
  9. R. Chan and L. Z. Benet, “Evaluation of DILI predictive hypotheses in early drug development,” Chemical Research in Toxicology, vol. 30, no. 4, pp. 1017–1029, 2017. View at: Publisher Site | Google Scholar
  10. C. Lammert, S. Einarsson, C. Saha, A. Niklasson, E. Bjornsson, and N. Chalasani, “Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals,” Hepatology, vol. 47, no. 6, pp. 2003–2009, 2008. View at: Publisher Site | Google Scholar
  11. R. A. Thompson, E. M. Isin, M. O. Ogese, J. T. Mettetal, and D. P. Williams, “Reactive metabolites: current and emerging risk and hazard assessments,” Chemical Research in Toxicology, vol. 29, no. 4, pp. 505–533, 2016. View at: Publisher Site | Google Scholar
  12. M. I. Lucena, M. Molokhia, Y. Shen et al., “Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles,” Gastroenterology, vol. 141, no. 1, pp. 338–347, 2011. View at: Publisher Site | Google Scholar
  13. Q. You, L. Cheng, T. P. Reilly, D. Wegmann, and C. Ju, “Role of neutrophils in a mouse model of halothane-induced liver injury,” Hepatology, vol. 44, no. 6, pp. 1421–1431, 2006. View at: Publisher Site | Google Scholar
  14. S. H. Kim, K. Saide, J. Farrell et al., “Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury,” Hepatology, vol. 62, no. 3, pp. 887–899, 2015. View at: Publisher Site | Google Scholar
  15. Y. Li, K. Wong, A. Giles et al., “Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21,” Gastroenterology, vol. 146, no. 2, pp. 539–549.e7, 2014. View at: Publisher Site | Google Scholar
  16. A. Brunet, L. B. Sweeney, J. F. Sturgill et al., “Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase,” Science, vol. 303, no. 5666, pp. 2011–2015, 2004. View at: Publisher Site | Google Scholar
  17. W. Y. Chen, D. H. Wang, R. W. C. Yen, J. Luo, W. Gu, and S. B. Baylin, “Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses,” Cell, vol. 123, no. 3, pp. 437–448, 2005. View at: Publisher Site | Google Scholar
  18. M. M. Bellet, S. Masri, G. Astarita, P. Sassone-Corsi, M. A. Della Fazia, and G. Servillo, “Histone deacetylase SIRT1 controls proliferation, circadian rhythm, and lipid metabolism during liver regeneration in Mice,” J Biol Chem, vol. 291, no. 44, pp. 23318–23329, 2016. View at: Publisher Site | Google Scholar
  19. T. Ramirez, Y. M. Li, S. Yin et al., “Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression,” Journal of Hepatology, vol. 66, no. 3, pp. 601–609, 2017. View at: Publisher Site | Google Scholar
  20. S. R. Kulkarni, C. J. Soroka, L. R. Hagey, and J. L. Boyer, “Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis,” Hepatology, vol. 64, no. 6, pp. 2151–2164, 2016. View at: Publisher Site | Google Scholar
  21. J. Zhang, L. Xu, L. Zhang, Z. Ying, W. Su, and T. Wang, “Curcumin Attenuates D-Galactosamine/Lipopolysaccharide–Induced Liver Injury and Mitochondrial Dysfunction in Mice,” The Journal of Nutrition, vol. 144, no. 8, pp. 1211–1218, 2014. View at: Publisher Site | Google Scholar
  22. P. Rada, V. Pardo, M. A. Mobasher et al., “SIRT1 controls acetaminophen hepatotoxicity by modulating inflammation and oxidative stress,” Antioxidants & Redox Signaling, vol. 28, no. 13, pp. 1187–1208, 2018. View at: Publisher Site | Google Scholar
  23. Y. Wang, Y. Jiang, X. Fan et al., “Hepato-protective effect of resveratrol against acetaminophen-induced liver injury is associated with inhibition of CYP-mediated bioactivation and regulation of SIRT1-p53 signaling pathways,” Toxicology Letters, vol. 236, no. 2, pp. 82–89, 2015. View at: Publisher Site | Google Scholar
  24. L. Wojnarová, N. K. Canová, H. Farghali, and T. Kucera, “Sirtuin 1 modulation in rat model of acetaminophen-induced hepatotoxicity,” Physiological Research, vol. 64, Suppl 4, pp. S477–S487, 2015. View at: Google Scholar
  25. X. Cui, Q. Chen, Z. Dong et al., “Inactivation of Sirt1 in mouse livers protects against endotoxemic liver injury by acetylating and activating NF-κB,” Cell Death & Disease, vol. 7, no. 10, p. e2403, 2016. View at: Publisher Site | Google Scholar
  26. C. Hao, P.-X. Zhu, X. Yang et al., “Overexpression of SIRT1 promotes metastasis through epithelial-mesenchymal transition in hepatocellular carcinoma,” BMC Cancer, vol. 14, no. 1, 2014. View at: Publisher Site | Google Scholar
  27. R. Al-Bahrani, D. Tuertcher, S. Zailaie et al., “Differential SIRT1 expression in hepatocellular carcinomas and cholangiocarcinoma of the liver,” Annals of Clinical & Laboratory Science, vol. 45, no. 1, pp. 3–9, 2015. View at: Google Scholar
  28. S. Kumar and D. B. Lombard, “Mitochondrial sirtuins and their relationships with metabolic disease and cancer,” Antioxidants & Redox Signaling, vol. 22, no. 12, pp. 1060–1077, 2015. View at: Publisher Site | Google Scholar
  29. K. R. Olson, A. H. Davarpanah, E. A. Schaefer, N. Elias, and J. Misdraji, “Case 2-2017 — An 18-Year-Old Woman with Acute Liver Failure,” New England Journal of Medicine, vol. 376, no. 3, pp. 268–278, 2017. View at: Publisher Site | Google Scholar
  30. R. J. Fontana, “Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives,” Gastroenterology, vol. 146, no. 4, pp. 914–928.e1, 2014. View at: Publisher Site | Google Scholar
  31. F. J. Cubero, M. E. Zoubek, W. Hu et al., “Combined activities of JNK1 and JNK2 in hepatocytes protect against toxic liver injury,” Gastroenterology, vol. 150, no. 4, pp. 968–981, 2016. View at: Publisher Site | Google Scholar
  32. S. Bedda, A. Laurent, F. Conti et al., “Mangafodipir prevents liver injury induced by acetaminophen in the mouse,” Journal of Hepatology, vol. 39, no. 5, pp. 765–772, 2003. View at: Publisher Site | Google Scholar
  33. Z. X. Liu, S. Govindarajan, and N. Kaplowitz, “Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity,” Gastroenterology, vol. 127, no. 6, pp. 1760–1774, 2004. View at: Publisher Site | Google Scholar
  34. P. C. Burcham and A. W. Harman, “Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes,” Journal of Biological Chemistry, vol. 266, no. 8, pp. 5049–5054, 1991. View at: Google Scholar
  35. M. R. McGill, M. Lebofsky, H. R. K. Norris et al., “Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications,” Toxicology and Applied Pharmacology, vol. 269, no. 3, pp. 240–249, 2013. View at: Publisher Site | Google Scholar
  36. R. Hanczko, D. R. Fernandez, E. Doherty et al., “Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine,” Journal of Clinical Investigation, vol. 119, no. 6, pp. 1546–1557, 2009. View at: Publisher Site | Google Scholar
  37. M. J. Gomez-Lechon, L. Tolosa, and M. T. Donato, “Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs,” Journal of Applied Toxicology, vol. 36, no. 6, pp. 752–768, 2016. View at: Publisher Site | Google Scholar
  38. P. Gong and A. I. Cederbaum, “Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1,” Hepatology, vol. 43, no. 1, pp. 144–153, 2006. View at: Publisher Site | Google Scholar
  39. S. H. Bae, S. H. Sung, S. Y. Oh et al., “Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage,” Cell Metabolism, vol. 17, no. 1, pp. 73–84, 2013. View at: Publisher Site | Google Scholar
  40. I. M. Copple, C. E. Goldring, R. E. Jenkins et al., “The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system,” Hepatology, vol. 48, no. 4, pp. 1292–1301, 2008. View at: Publisher Site | Google Scholar
  41. K. Otani, M. Korenaga, M. R. Beard et al., “Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells,” Gastroenterology, vol. 128, no. 1, pp. 96–107, 2005. View at: Publisher Site | Google Scholar
  42. C. Y. Han, S. W. Lim, J. H. Koo, W. Kim, and S. G. Kim, “PHLDA3 overexpression in hepatocytes by endoplasmic reticulum stress via IRE1-Xbp1s pathway expedites liver injury,” Gut, vol. 65, no. 8, pp. 1377–1388, 2016. View at: Publisher Site | Google Scholar
  43. X. Jin, Z. Zhang, D. Beer-Stolz, T. A. Zimmers, and L. G. Koniaris, “Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection,” Hepatology, vol. 46, no. 3, pp. 802–812, 2007. View at: Publisher Site | Google Scholar
  44. J. Karch, J. Q. Kwong, A. R. Burr et al., “Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice,” Elife, vol. 2, article e00772, no. 2, 2013. View at: Publisher Site | Google Scholar
  45. Y. Masubuchi, C. Suda, and T. Horie, “Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice,” Journal of Hepatology, vol. 42, no. 1, pp. 110–116, 2005. View at: Publisher Site | Google Scholar
  46. A. M. Byrne, J. J. Lemasters, and A. L. Nieminen, “Contribution of increased mitochondrial free Ca2+ to the mitochondrial permeability transition induced by tert-butylhydroperoxide in rat hepatocytes,” Hepatology, vol. 29, no. 5, pp. 1523–1531, 1999. View at: Publisher Site | Google Scholar
  47. I. R. Wanless, S. Dore, N. Gopinath et al., “Histopathology of cocaine hepatotoxicity,” Gastroenterology, vol. 98, no. 2, pp. 497–501, 1990. View at: Publisher Site | Google Scholar
  48. K. Y. Hur, J. S. So, V. Ruda et al., “IRE1α activation protects mice against acetaminophen-induced hepatotoxicity,” The Journal of Experimental Medicine, vol. 209, no. 2, pp. 307–318, 2012. View at: Publisher Site | Google Scholar
  49. D. Uzi, L. Barda, V. Scaiewicz et al., “CHOP is a critical regulator of acetaminophen-induced hepatotoxicity,” Journal of Hepatology, vol. 59, no. 3, pp. 495–503, 2013. View at: Publisher Site | Google Scholar
  50. M. E. Letelier, M. López-Valladares, L. Peredo-Silva, D. Rojas-Sepúlveda, and P. Aracena, “Microsomal oxidative damage promoted by acetaminophen metabolism,” Toxicology in Vitro, vol. 25, no. 7, pp. 1310–1313, 2011. View at: Publisher Site | Google Scholar
  51. G. Nagy, T. Kardon, L. Wunderlich et al., “Acetaminophen induces ER dependent signaling in mouse liver,” Archives of Biochemistry and Biophysics, vol. 459, no. 2, pp. 273–279, 2007. View at: Publisher Site | Google Scholar
  52. N. Y. Shin, Q. Liu, S. L. Stamer, and D. C. Liebler, “Protein targets of reactive electrophiles in human liver microsomes,” Chemical Research in Toxicology, vol. 20, no. 6, pp. 859–867, 2007. View at: Publisher Site | Google Scholar
  53. S. H. Bae, S. H. Sung, H. E. Lee et al., “Peroxiredoxin III and sulfiredoxin together protect mice from pyrazole-induced oxidative liver injury,” Antioxidants & Redox Signaling, vol. 17, no. 10, pp. 1351–1361, 2012. View at: Publisher Site | Google Scholar
  54. R. Hoque, A. Farooq, A. Ghani, F. Gorelick, and W. Z. Mehal, “Lactate reduces liver and pancreatic injury in Toll-like receptor- and inflammasome-mediated inflammation via GPR81-mediated suppression of innate immunity,” Gastroenterology, vol. 146, no. 7, pp. 1763–1774, 2014. View at: Publisher Site | Google Scholar
  55. I. Downs, T. Y. Aw, J. Liu, P. Adegboyega, and M. N. Ajuebor, “Vα14iNKT cell deficiency prevents acetaminophen-induced acute liver failure by enhancing hepatic glutathione and altering APAP metabolism,” Biochemical and Biophysical Research Communications, vol. 428, no. 2, pp. 245–251, 2012. View at: Publisher Site | Google Scholar
  56. P. Huebener, J. P. Pradere, C. Hernandez et al., “The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis,” Journal of Clinical Investigation, vol. 125, no. 2, pp. 539–550, 2015. View at: Publisher Site | Google Scholar
  57. Y. Nadatani, T. Watanabe, T. Tanigawa et al., “High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4,” The American Journal of Pathology, vol. 181, no. 1, pp. 98–110, 2012. View at: Publisher Site | Google Scholar
  58. W. Wang, L. Sun, Y. Deng, and J. Tang, “Synergistic effects of antibodies against high-mobility group box 1 and tumor necrosis factor-α antibodies ond-(+)-galactosamine hydrochloride/lipopolysaccharide-induced acute liver failure,” FEBS Journal, vol. 280, no. 6, pp. 1409–1419, 2013. View at: Publisher Site | Google Scholar
  59. N. N. Zhang, N. Y. Huang, X. K. Zhou et al., “Protective effects of IL-4 on Bacillus Calmette-Guerin and lipopolysaccharide induced immunological liver injury in mice,” Inflamm Res, vol. 61, no. 1, pp. 17–26, 2012. View at: Publisher Site | Google Scholar
  60. A. F. Paroli, P. V. Gonzalez, C. Díaz-Luján et al., “NLRP3 inflammasome and caspase-1/11 pathway orchestrate different outcomes in the host protection against Trypanosoma cruzi acute infection,” Frontiers in Immunology, vol. 9, p. 913, 2018. View at: Publisher Site | Google Scholar
  61. B. V. Martin-Murphy, D. J. Kominsky, D. J. Orlicky, T. M. Donohue Jr, and C. Ju, “Increased susceptibility of natural killer T-cell-deficient mice to acetaminophen-induced liver injury,” Hepatology, vol. 57, no. 4, pp. 1575–1584, 2013. View at: Publisher Site | Google Scholar
  62. M. S. Tsai, C. C. Chien, T. H. Lin et al., “Galangin prevents acute hepatorenal toxicity in novel propacetamol-induced acetaminophen-overdosed mice,” Journal of Medicinal Food, vol. 18, no. 11, pp. 1187–1197, 2015. View at: Publisher Site | Google Scholar
  63. W. Khamri, R. D. Abeles, T. Z. Hou et al., “Increased expression of cytotoxic T-lymphocyte-associated protein 4 by T cells, induced by B7 in sera, reduces adaptive immunity in patients with acute liver failure,” Gastroenterology, vol. 153, no. 1, pp. 263–276.e8, 2017. View at: Publisher Site | Google Scholar
  64. L. Li, W. Jiang, and J. Wang, “Clinical analysis of 275 cases of acute drug-induced liver disease,” Frontiers of Medicine in China, vol. 1, no. 1, pp. 58–61, 2007. View at: Publisher Site | Google Scholar
  65. Y.-c. Yu, Drug-induced Liver Injury (DILI) Study Group, Y.-m. Mao et al., “CSH guidelines for the diagnosis and treatment of drug-induced liver injury,” Hepatology International, vol. 11, no. 3, pp. 221–241, 2017. View at: Publisher Site | Google Scholar
  66. N. P. Chalasani, on behalf of the Practice Parameters Committee of the American College of Gastroenterology, P. H. Hayashi et al., “ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury,” The American Journal of Gastroenterology, vol. 109, no. 7, pp. 950–966, 2014. View at: Publisher Site | Google Scholar
  67. Y. M. Mao, M. D. Zeng, Y. Chen et al., “Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study,” Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, vol. 17, no. 11, pp. 847–851, 2009. View at: Google Scholar
  68. A. Reuben, D. G. Koch, W. M. Lee, and Acute Liver Failure Study Group, “Drug-induced acute liver failure: results of a U.S. multicenter, prospective study,” Hepatology, vol. 52, no. 6, pp. 2065–2076, 2010. View at: Publisher Site | Google Scholar
  69. G. Labbe, D. Pessayre, and B. Fromenty, “Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies,” Fundamental & Clinical Pharmacology, vol. 22, no. 4, pp. 335–353, 2008. View at: Publisher Site | Google Scholar
  70. X. Chao, S. Wang, K. Zhao et al., “Impaired TFEB-mediated lysosome biogenesis and autophagy promote chronic ethanol-induced liver injury and steatosis in mice,” Gastroenterology, vol. 155, no. 3, pp. 865–879.e12, 2018. View at: Publisher Site | Google Scholar
  71. H. Fujii and N. Kawada, “Fibrogenesis in alcoholic liver disease,” World Journal of Gastroenterology, vol. 20, no. 25, pp. 8048–8054, 2014. View at: Publisher Site | Google Scholar
  72. J. W. Park, M. Chen, M. Colombo et al., “Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study,” Liver International, vol. 35, no. 9, pp. 2155–2166, 2015. View at: Publisher Site | Google Scholar
  73. Y. Minokoshi, Y. B. Kim, O. D. Peroni et al., “Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase,” Nature, vol. 415, no. 6869, pp. 339–343, 2002. View at: Publisher Site | Google Scholar
  74. M. D. Fullerton, S. Galic, K. Marcinko et al., “Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin,” Nature Medicine, vol. 19, no. 12, pp. 1649–1654, 2013. View at: Publisher Site | Google Scholar
  75. Q. Cheng, Y. W. Li, C. F. Yang et al., “Methyl ferulic acid attenuates ethanol-induced hepatic steatosis by regulating AMPK and FoxO1 pathways in rats and L-02 cells,” Chemico-Biological Interactions, vol. 291, pp. 180–189, 2018. View at: Publisher Site | Google Scholar
  76. Y. Lee, X. Yu, F. Gonzales et al., “PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue,” Proceedings of the National Academy of Sciences, vol. 99, no. 18, pp. 11848–11853, 2002. View at: Publisher Site | Google Scholar
  77. T. M. Leung, Y. Lu, W. Yan et al., “Argininosuccinate synthase conditions the response to acute and chronic ethanol-induced liver injury in mice,” Hepatology, vol. 55, no. 5, pp. 1596–1609, 2012. View at: Publisher Site | Google Scholar
  78. A. Purushotham, T. T. Schug, Q. Xu, S. Surapureddi, X. Guo, and X. Li, “Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation,” Cell Metabolism, vol. 9, no. 4, pp. 327–338, 2009. View at: Publisher Site | Google Scholar
  79. N. F. Nicoletti, V. Rodrigues-Junior, A. A. Santos Jr et al., “Protective effects of resveratrol on hepatotoxicity induced by isoniazid and rifampicin via SIRT1 modulation,” Journal of Natural Products, vol. 77, no. 10, pp. 2190–2195, 2014. View at: Publisher Site | Google Scholar
  80. A. Vidal-Puig, M. Jimenez-Liñan, B. B. Lowell et al., “Regulation of PPAR gamma gene expression by nutrition and obesity in rodents,” Journal of Clinical Investigation, vol. 97, no. 11, pp. 2553–2561, 1996. View at: Publisher Site | Google Scholar
  81. F. Picard, M. Kurtev, N. Chung et al., “Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma,” Nature, vol. 429, no. 6993, pp. 771–776, 2004. View at: Publisher Site | Google Scholar
  82. Y. Yang, T. Bai, Y. L. Yao et al., “Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury,” Toxicology Letters, vol. 262, pp. 80–91, 2016. View at: Publisher Site | Google Scholar
  83. A. Y. Na, E. J. Yang, J. M. Jeon, S. H. Ki, K. S. Song, and S. Lee, “Protective effect of isoliquiritigenin against ethanol-induced hepatic steatosis by regulating the SIRT1-AMPK pathway,” Toxicological Research, vol. 34, no. 1, pp. 23–29, 2018. View at: Publisher Site | Google Scholar
  84. Y. Zu, L. Liu, M. Y. K. Lee et al., “SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells,” Circulation Research, vol. 106, no. 8, pp. 1384–1393, 2010. View at: Publisher Site | Google Scholar
  85. G. Sadi, V. Ergin, G. Yilmaz et al., “High-fructose corn syrup-induced hepatic dysfunction in rats: improving effect of resveratrol,” European Journal of Nutrition, vol. 54, no. 6, pp. 895–904, 2015. View at: Publisher Site | Google Scholar
  86. D. Yang, X. Tan, Z. Lv et al., “Regulation of Sirt1/Nrf2/TNF-α signaling pathway by luteolin is critical to attenuate acute mercuric chloride exposure induced hepatotoxicity,” Scientific Reports, vol. 6, no. 1, 2016. View at: Publisher Site | Google Scholar
  87. T. Adachi, H. Nakagawa, I. Chung et al., “Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress,” Journal of Experimental Therapeutics and Oncology, vol. 6, no. 4, pp. 335–348, 2007. View at: Google Scholar
  88. S. R. Kulkarni, A. C. Donepudi, J. Xu et al., “Fasting induces nuclear factor E2-related factor 2 and ATP-binding cassette transporters via protein kinase A and Sirtuin-1 in mouse and human,” Antioxidants & Redox Signaling, vol. 20, no. 1, pp. 15–30, 2014. View at: Publisher Site | Google Scholar
  89. Y. Wan, Y.-L. Wu, X.-C. Feng, L.-H. Lian, Y.-Z. Jiang, and J.-X. Nan, “The protective effects of total saponins from Ornithogalum saundersiae (Liliaceae) on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice,” Journal of Ethnopharmacology, vol. 132, no. 2, pp. 450–455, 2010. View at: Publisher Site | Google Scholar
  90. J. J. Chen and B. P. Yu, “Alterations in mitochondrial membrane fluidity by lipid peroxidation products,” Free Radical Biology and Medicine, vol. 17, no. 5, pp. 411–418, 1994. View at: Publisher Site | Google Scholar
  91. J. Jacobson and M. R. Duchen, “Mitochondrial oxidative stress and cell death in astrocytes--requirement for stored Ca2+ and sustained opening of the permeability transition pore,” Journal of Cell Science, vol. 115, no. 6, pp. 1175–1188, 2002. View at: Google Scholar
  92. S. Sun, M. Zhang, Q. Yang et al., “Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models,” Molecular Nutrition & Food Research, vol. 61, no. 10, 2017. View at: Publisher Site | Google Scholar
  93. P. Li, X. Wang, M. Zhao, R. Song, and K. S. Zhao, “Polydatin protects hepatocytes against mitochondrial injury in acute severe hemorrhagic shock via SIRT1-SOD2 pathway,” Expert Opinion on Therapeutic Targets, vol. 19, no. 7, pp. 997–1010, 2015. View at: Publisher Site | Google Scholar
  94. S. Miltonprabu, Nazimabashir, and V. Manoharan, “Hepatoprotective effect of grape seed proanthocyanidins on Cadmium-induced hepatic injury in rats: Possible involvement of mitochondrial dysfunction, inflammation and apoptosis,” Toxicology Reports, vol. 3, pp. 63–77, 2016. View at: Publisher Site | Google Scholar
  95. M. Tan, C. Tang, Y. Zhang et al., “SIRT1/PGC-1α signaling protects hepatocytes against mitochondrial oxidative stress induced by bile acids,” Free Radical Research, vol. 49, no. 8, pp. 935–945, 2015. View at: Publisher Site | Google Scholar
  96. P. Guo, H. Pi, S. Xu et al., “Melatonin Improves mitochondrial function by promoting MT1/SIRT1/PGC-1 alpha-dependent mitochondrial biogenesis in cadmium-induced hepatotoxicity in vitro,” Toxicological Sciences, vol. 142, no. 1, pp. 182–195, 2014. View at: Publisher Site | Google Scholar
  97. J. H. Pan, Y. Lim, J. H. Kim et al., “Root bark of Ulmus davidiana var. japonica restrains acute alcohol-induced hepatic steatosis onset in mice by inhibiting ROS accumulation,” PLoS One, vol. 12, no. 11, article e0188381, 2017. View at: Publisher Site | Google Scholar
  98. C. Yang, L. Li, Z. Ma et al., “Hepatoprotective effect of methyl ferulic acid against carbon tetrachloride-induced acute liver injury in rats,” Experimental and Therapeutic Medicine, vol. 15, no. 3, pp. 2228–2238, 2018. View at: Publisher Site | Google Scholar
  99. M. Tahir, M. U. Rehman, A. Lateef et al., “Diosmin protects against ethanol-induced hepatic injury via alleviation of inflammation and regulation of TNF-α and NF-κB activation,” Alcohol, vol. 47, no. 2, pp. 131–139, 2013. View at: Publisher Site | Google Scholar
  100. Y. Kuang, X. Han, M. Xu, Y. Wang, Y. Zhao, and Q. Yang, “Oxaloacetate ameliorates chemical liver injury via oxidative stress reduction and enhancement of bioenergetic fluxes,” International Journal of Molecular Sciences, vol. 19, no. 6, p. 1626, 2018. View at: Publisher Site | Google Scholar
  101. G. Xu, Z. Zhang, Y. Xing et al., “MicroRNA-149 negatively regulates TLR-triggered inflammatory response in macrophages by targeting MyD88,” Journal of Cellular Biochemistry, vol. 115, no. 5, pp. 919–927, 2014. View at: Publisher Site | Google Scholar
  102. F. Yeung, J. E. Hoberg, C. S. Ramsey et al., “Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase,” The EMBO Journal, vol. 23, no. 12, pp. 2369–2380, 2004. View at: Publisher Site | Google Scholar
  103. J. Luo, A. Y. Nikolaev, S. Imai et al., “Negative control of p53 by Sir2alpha promotes cell survival under stress,” Cell, vol. 107, no. 2, pp. 137–148, 2001. View at: Google Scholar
  104. X. Xu, Y. Hu, X. Zhai et al., “Salvianolic acid A preconditioning confers protection against concanavalin A-induced liver injury through SIRT1-mediated repression of p66shc in mice,” Toxicology and Applied Pharmacology, vol. 273, no. 1, pp. 68–76, 2013. View at: Publisher Site | Google Scholar
  105. J. Zhang, S. M. Lee, S. Shannon et al., “The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice,” Journal of Clinical Investigation, vol. 119, no. 10, pp. 3048–3058, 2009. View at: Publisher Site | Google Scholar
  106. W. Zhang, L. Yin, X. Tao et al., “Dioscin alleviates dimethylnitrosamine-induced acute liver injury through regulating apoptosis, oxidative stress and inflammation,” Environmental Toxicology and Pharmacology, vol. 45, pp. 193–201, 2016. View at: Publisher Site | Google Scholar
  107. A. F. M. Ismail, A. A. M. Salem, and M. M. T. Eassawy, “Hepatoprotective effect of grape seed oil against carbon tetrachloride induced oxidative stress in liver of γ-irradiated rat,” Journal of Photochemistry and Photobiology B: Biology, vol. 160, pp. 1–10, 2016. View at: Publisher Site | Google Scholar
  108. M. M. Rabadi, S. Xavier, R. Vasko, K. Kaur, M. S. Goligorksy, and B. B. Ratliff, “High-mobility group box 1 is a novel deacetylation target of Sirtuin1,” Kidney International, vol. 87, no. 1, pp. 95–108, 2015. View at: Publisher Site | Google Scholar
  109. W. Xu, Y. Lu, J. Yao et al., “Novel role of resveratrol: suppression of high-mobility group protein box 1 nucleocytoplasmic translocation by the upregulation of sirtuin 1 in sepsis-induced liver injury,” Shock, vol. 42, no. 5, pp. 440–447, 2014. View at: Publisher Site | Google Scholar
  110. L. Yu, X. Liu, X. Li et al., “Protective effects of SRT1720 via the HNF1α/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury,” Toxicology Letters, vol. 264, pp. 1–11, 2016. View at: Publisher Site | Google Scholar
  111. C. García-Ruiz, A. Morales, A. Ballesta, J. Rodés, N. Kaplowitz, and J. C. Fernández-Checa, “Effect of chronic ethanol feeding on glutathione and functional integrity of mitochondria in periportal and perivenous rat hepatocytes,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 193–201, 1994. View at: Publisher Site | Google Scholar
  112. X. Tian, Y. Hu, M. Li et al., “Carnosic acid attenuates acute ethanol-induced liver injury via a SIRT1/p66Shc-mediated mitochondrial pathway,” Canadian Journal of Physiology and Pharmacology, vol. 94, no. 4, pp. 416–425, 2016. View at: Publisher Site | Google Scholar
  113. L. Gao, W. Shan, W. Zeng et al., “Carnosic acid alleviates chronic alcoholic liver injury by regulating the SIRT1/ChREBP and SIRT1/p66shc pathways in rats,” Molecular Nutrition & Food Research, vol. 60, no. 9, pp. 1902–1911, 2016. View at: Publisher Site | Google Scholar
  114. G. P. Sreekanth, A. Chuncharunee, B. Cheunsuchon, S. Noisakran, P. T. Yenchitsomanus, and T. Limjindaporn, “JNK1/2 inhibitor reduces dengue virus-induced liver injury,” Antiviral Research, vol. 141, pp. 7–18, 2017. View at: Publisher Site | Google Scholar
  115. L. Gu, X. Tao, Y. Xu et al., “Dioscin alleviates BDL- and DMN-induced hepatic fibrosis via Sirt1/Nrf2-mediated inhibition of p38 MAPK pathway,” Toxicology and Applied Pharmacology, vol. 292, pp. 19–29, 2016. View at: Publisher Site | Google Scholar
  116. Y. Zhang, X. Liu, Z. G. She et al., “Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury,” Basic Research in Cardiology, vol. 109, no. 5, p. 434, 2014. View at: Publisher Site | Google Scholar
  117. K. Höpker, H. Hagmann, S. Khurshid et al., “AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis,” The EMBO Journal, vol. 31, no. 20, pp. 3961–3975, 2012. View at: Publisher Site | Google Scholar
  118. X. Liu, X. Yang, L. Han et al., “Pterostilbene alleviates polymicrobial sepsis-induced liver injury: possible role of SIRT1 signaling,” International Immunopharmacology, vol. 49, pp. 50–59, 2017. View at: Publisher Site | Google Scholar
  119. H. Yao, X. Tao, L. Xu et al., “Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway,” Pharmacological Research, vol. 131, pp. 51–60, 2018. View at: Publisher Site | Google Scholar
  120. W. X. Zong, C. Li, G. Hatzivassiliou et al., “Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis,” The Journal of Cell Biology, vol. 162, no. 1, pp. 59–69, 2003. View at: Publisher Site | Google Scholar
  121. S. Orrenius, B. Zhivotovsky, and P. Nicotera, “Regulation of cell death: the calcium-apoptosis link,” Nature Reviews Molecular Cell Biology, vol. 4, no. 7, pp. 552–565, 2003. View at: Publisher Site | Google Scholar
  122. J. Rojo-Ruiz, M. Rodríguez-Prados, A. Delrio-Lorenzo, M. T. Alonso, and J. García-Sancho, “Caffeine chelates calcium in the lumen of the endoplasmic reticulum,” Biochemical Journal, vol. 475, no. 22, pp. 3639–3649, 2018. View at: Publisher Site | Google Scholar
  123. B. Gan, X. Peng, T. Nagy, A. Alcaraz, H. Gu, and J. L. Guan, “Role of FIP200 in cardiac and liver development and its regulation of TNFα and TSC–mTOR signaling pathways,” The Journal of Cell Biology, vol. 175, no. 1, pp. 121–133, 2006. View at: Publisher Site | Google Scholar
  124. D. Han, X. Li, S. Li et al., “Reduced silent information regulator 1 signaling exacerbates sepsis-induced myocardial injury and mitigates the protective effect of a liver X receptor agonist,” Free Radical Biology and Medicine, vol. 113, pp. 291–303, 2017. View at: Publisher Site | Google Scholar
  125. C. Y. Wang, M. W. Mayo, R. G. Korneluk, D. V. Goeddel, and Baldwin AS Jr, “NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation,” Science, vol. 281, no. 5383, pp. 1680–1683, 1998. View at: Publisher Site | Google Scholar
  126. B. A. Mayer, M. Rehberg, A. Erhardt et al., “Inhibitor of apoptosis proteins as novel targets in inflammatory processes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 10, pp. 2240–2250, 2011. View at: Publisher Site | Google Scholar
  127. Y. Lee, G. S. Jeong, K. M. Kim, W. Lee, and J. S. Bae, “Cudratricusxanthone A attenuates sepsis-induced liver injury via SIRT1 signaling,” Journal of Cellular Physiology, vol. 233, no. 7, pp. 5441–5446, 2018. View at: Publisher Site | Google Scholar
  128. X. Sun, P. Wang, L. P. Yao et al., “Paeonol alleviated acute alcohol-induced liver injury via SIRT1/Nrf2/NF-κB signaling pathway,” Environmental Toxicology and Pharmacology, vol. 60, pp. 110–117, 2018. View at: Publisher Site | Google Scholar
  129. T. Ueno and M. Komatsu, “Autophagy in the liver: functions in health and disease,” Nature Reviews Gastroenterology & Hepatology, vol. 14, no. 3, pp. 170–184, 2017. View at: Publisher Site | Google Scholar
  130. R. Singh, S. Kaushik, Y. Wang et al., “Autophagy regulates lipid metabolism,” Nature, vol. 458, no. 7242, pp. 1131–1135, 2009. View at: Publisher Site | Google Scholar
  131. H. M. Ni, K. du, M. You, and W. X. Ding, “Critical role of FoxO3a in alcohol-induced autophagy and hepatotoxicity,” The American Journal of Pathology, vol. 183, no. 6, pp. 1815–1825, 2013. View at: Publisher Site | Google Scholar
  132. M. S. Tsai, Y. H. Wang, Y. Y. Lai et al., “Kaempferol protects against propacetamol-induced acute liver injury through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress, inflammation and apoptosis in mice,” Toxicol Lett, vol. 290, pp. 97–109, 2018. View at: Publisher Site | Google Scholar

Copyright © 2019 Tingdong Yan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

874 Views | 391 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.